The U.S. Food and Drug Administration (FDA) has cleared the start of a Phase 2 trial of izokibep in…
Shayna Korol
Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Shayna Korol
The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected…
Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography…
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the…
The U.S. Food and Drug Administration (FDA) has approved Hulio, a biosimilar of Humira (adalimumab), to treat chronic inflammatory…
The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure…
The Alexion Charitable Foundation has awarded $1.1 million in grants to programs that support those with rare diseases during…
Nepexto, a biosimilar to Enbrel (etanercept), has been approved by the European Commission to treat ankylosing…
The Black Women’s Health Imperative (BWHI) recently created a Rare Disease Diversity Coalition focused on reducing racial disparities in…
Around 2,000 patients across the U.K. with ankylosing spondylitis (AS), psoriatic arthritis, or chronic pain conditions such as fibromyalgia will…